Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by lonc17on Jan 06, 2007 11:56pm

485 Views

Post# 11968359

nci - mayo trial

From an email exchange with the principal investigator in the ONC NCI mayo trial I have learned that it will 'hopefully' begin in early spring and that things are progressing on schedule 'as expected' By the way, does anyone else think that things are building up quickly for a major partnership announcement?

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages